EP2205262A2 - Use of melanotropin-potentiating factor as a ...,https://www.google.com/patents/EP2205262A2
EP2190453A2 - Utilisation de la trp6-triptor√©line et du d-leu6 ...,https://www.google.com/patents/EP2190453A2?cl=fr
WO2009046874A1 - Therapeutic combination of trh-potentiating ...,https://www.google.com/patents/WO2009046874A1?cl=pt
WO2009046877A2 - Use of a histrelin and leuprolide as therapeutic ...,https://www.google.com/patents/WO2009046877A2?cl=pt
EP2187940B1 - Use of urocortin optionally together with ...,https://www.google.com/patents/EP2187940B1?cl=da
CA2699107A1 - Use of a platelet fibrinogen receptor hexapeptide ...,https://www.google.com/patents/CA2699107A1?cl=enIt
CA2698770A1 - Use of secretin and optionally urodilatin as a ...,https://www.google.com/patents/CA2698770A1?cl=ko
EP2187936A1 - Minigastrin as a therapeutic agent - Google Patents,https://www.google.com/patents/EP2187936A1?cl=pt
WO2009033802A2 - Antide as a therapeutic agent - Google Patents,https://www.google.com/patents/WO2009033802A2?cl=en20
WO2009043449A2 - Use of a peptide as a therapeutic agent ...,https://www.google.com/patents/WO2009043449A2?cl=de
